ADRe Profile Surfaces Hidden Medication Harms in Primary Care

This small cluster-randomised trial shows a structured, patient-completed adverse drug reaction monitoring tool can identify and resolve unrecognised medication-related problems in polypharmacy patients that never reach the medical record.

ADRe Profilemedication safetypolypharmacydeprescribingadverse drug reactionsprimary careolder adultscluster RCTmedicines optimisationpharmacist reviewflecainidemetforminvitamin B12 Medication Safety

Background Information

ADRe Profile improves medication safety for elderly on multiple prescriptions.

Incomplete monitoring of repeat prescriptions can lead to avoidable harm, especially in older adults on multiple medications. The intervention group using the Adverse Drug Reaction (ADRe) Profile had more problems addressed compared to controls (82% vs. 35%, adjusted odds ratio 7.48, 95% CI 1.99 to 28.10). The study shows that the ADRe Profile can significantly benefit patients by identifying and addressing clinical problems; however, implementation challenges exist regarding staff time. The ADRe Profile effectively reduces risk of suboptimal prescribing and iatrogenic harm in primary care.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Logan V, Conboy A, Carter N, Hughes D, Turner A, Watkins A, Jordan S

Citation: Logan V, Conboy A, Carter N, et al. "A better system" - managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care. PloS one. 2026;21(9):e0356480. doi:10.1371/journal.pone.0356480

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →